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Abstract
Background
Genetically determined Intellectual Disability (ID) is an intractable condition that involves
severe impairment of mental abilities such as learning, reasoning and predicting the future.
As of today, little is known about the placebo response in patients with ID.
Objective
To determine if placebo response exists in patients with genetically determined ID.
Data sources and Study selection
We searched Medline/PubMed, EMBASE, CENTRAL and PsycINFO to find all placebo-
controlled double-blind randomized clinical trials (RCTs) in patients with genetically deter-
mined ID, published up to April 2013, focusing on core ID symptoms.
Data extraction and synthesis
Two investigators extracted outcome data independently.
Main outcomes andmeasures
Bias-corrected standardized mean difference (Hedge’s g) was computed for each outcome
measure, using the Comprehensive Meta-Analysis software. A priori defined patient sub-
groups were analyzed using a mixed-effect model. The relationship between pre-defined
continuous variable moderators (age, IQ, year of publication and trial duration) and effect
size was analyzed using meta-regression
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Results
Twenty-two placebo-controlled double-blind RCTs met the inclusion criteria (n = 721, mean
age = 17.1 years, 62%men, mean trial duration = 35 weeks). There was a significant overall
placebo response from pre- to post-treatment in patients with ID (g = 0.468, p = 0.002), both
for “subjective outcomes” (a third-person’s evaluation of the patient) (g = 0.563, p = 0.022)
and “objective outcomes” (direct evaluation of the patient’s abilities) (g = 0.434, p = 0.036).
Individuals with higher IQ had higher response to placebo (p = 0.02) and no placebo
response was observed in ID patients with comorbid dementia. A significant effect of age
(p = 0.02) was found, indicating higher placebo responses in treatment of younger patients.
Conclusions and relevance
Results suggest that patients with genetically determined ID improve in the placebo arm of
RCTs. Several mechanisms may contribute to placebo effects in ID, including expectancy,
implicit learning and “placebo-by-proxy” induced by clinicians/family members. As the con-
dition is refractory, there is little risk that improvements are explained by spontaneous
remission. While new avenues for treatment of genetically determined ID are emerging, our
results demonstrate how contextual factors can affect clinical outcomes and emphasize the
importance of being vigilant on the role of placebos when testing novel treatments in ID.
Introduction
Intellectual Disability (ID) is characterized by deficits in intellectual functions, such as reason-
ing, abstract thinking, judgment and learning from experience. The defining features of ID are
confirmed by clinical assessment and standardized intelligence testing (overall Intelligence
Quotient (IQ)<70), combined with deficits in adaptive functioning that result in failure to
meet developmental and sociocultural standards, manifested during the developmental period
(DSM-V) [1]. Genetic causes of ID include visible chromosomal anomalies (such as Down’s
syndrome, which is the most frequent aneuploidy), chromosomal microdeletion (including
Prader-Willi and Williams’ syndrome) and monogenic diseases (such as mutation of the gene
FMR1 leading to Fragile X syndrome). None of these disorders improve spontaneously over
time. If anything, patients with Down’s syndrome risk an age-related cognitive decline after 40,
which progresses to Alzheimer’s-like dementia [2]. Until recently, treatment for ID focused
mainly on symptom management (including attention deficits and anxiety), and on minimiz-
ing the complications related to comorbidities (like epilepsy). New pharmacological treatment
options, that target the underlying defect related to each genetic mutation, are currently being
explored and may offer opportunities to directly improve cognition [3]. In spite of the emerg-
ing interest in cognitive improvement in ID, little is known about patients’ ability to improve
core ID symptoms as a response to placebo treatment. We decided to examine to what extent
placebo treatment in randomised controlled trials (RCTs) led to clinical improvement in
patients with ID. As current theories suggest that placebo effects depend on cognitive infer-
ences based on prior experience (learning) or treatment expectations (reasoning) [4], the severe
cognitive deficits in ID may challenge existing placebo models.
In clinical trials, placebo effects can be substantial and are often attributed to the expecta-
tions formed at the beginning of the trial, as studies show that the information content may
shape placebo outcomes [5]. Yet, little is known about the placebo response in individuals with
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limited ability to understand the significance of participating in a clinical trial. This is notewor-
thy, as the investigation of placebo responses in patients with ID may (i) elucidate the impact
of the “provision of care” independent of active medication [6], (ii) revise accepted theories of
placebo mechanisms that focus on learning and higher order cognition [4, 7, 8], and (iii)
improve the way clinical trials are performed and interpreted [9].
The brain mechanisms associated with placebo responses have been described in studies of
Parkinson disease [10, 11], pain [12–15], depression [16] and anxiety [17, 18] and suggest a
model of prefrontal cognitive control that modulates activity and neurotransmitter function
further down the neural axis. Even if subcortical structures [11, 17, 19], and even spinal struc-
tures [20, 21], have been associated with placebo responses, the role of executive brain function
is considered critical for processing the treatment expectations that create placebo responses.
However, recent evidence from our group suggest that human placebo mechanisms can oper-
ate outside of conscious awareness [22, 23], challenging the role of higher-order cognitions and
calling for closer investigation and refinement of the role of intellectual capacity in theories of
placebos.
Here, we used data from RCTs focusing on core ID symptoms (behavioral or cognitive
developmental functions) to investigate if patients with genetically determined ID display
placebo responses. To address the critical question of report bias, we compared the placebo
response to subjective (a third person’s evaluation of the patient, e.g., clinicians’ or parents’ rat-
ings) with more objective outcome measures (direct evaluation of the patient’s abilities, e.g.,
motor or memory task). By limiting our investigation to genetically determined syndromes we
controlled for the possibility that acquired ID (e.g. from childhood disease) could be an advan-
tage due normal brain development before ID onset. There is always a possibility that the pla-
cebo response is partially represented by spontaneous remission, or the natural history of the
condition being treated. Yet, genetically determined ID is a refractory condition [2], with little
likelihood of improvement due to spontaneous remission, rather than an effect of the treatment
intervention. Thanks to progress in molecular genetics, and a better knowledge about the phys-
iopathology of each disease, new avenues are emerging for treatment of genetically determined
ID, adding to the importance of understanding the placebo response in ID clinical trials.
Methods
Data source
We adhered to the PRISMA guidelines for reporting meta-analyses (www.prisma-statement.
org). We searched Medline/PubMed, EMBASE, CENTRAL and PsycINFO and restricted our
search to randomized placebo-controlled trials in patients with genetically determined ID from
one of the following diagnoses: Fragile X (FX), Down’s (DS), Prader-Willi’s (PW), and
Williams’ syndromes. The search terms ‘Randomized controlled trial’, ‘Clinical Trial’, ‘Thera-
peutics’ AND ‘Fragile X syndrome’, ‘Down’s syndrome’, ‘Prader-Willi’s syndrome’, ‘Williams
syndrome’ were used. All studies published before April 2013 were considered for inclusion.
Study selection
The criteria for inclusion were randomized double-blind placebo-controlled trials in patients
with one of the a priori defined genetically determined syndromes of ID, of any age. Studies
were excluded if (i) outcomes were not evaluation of behavioral or cognitive-developmental
functions (e.g. outcomes such as weight, height), (ii) if the treatment targeted a peripheral
comorbidity to intellectual disability (e.g. bone mass, acute lymphoblastic leukemia, supra-gin-
gival plaque accumulation). The selection of studies followed the Consolidated Standards Of
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Reporting Trials (CONSORT) guidelines to ensure adequate quality of included studies (www.
consort-statement.org).
Data extraction and quality assessment
Eligibility judgment of studies was performed in consensus meeting before extraction of data.
Studies were excluded if (i) the studies did not report any inference test or enough descriptive
information to compute an effect size (for instance, percentages or means and a variability
measure), (ii) less than five patients were included, (iii) no separate reports for drug/placebo
were available, (iv) not a randomized trial (placebo group added from previous study), (v) only
healthy controls were treated and no patients. All data was extracted independently by two sep-
arate reviewers (KY, KJ). Once all data was extracted, the values were compared and inconsis-
tencies were resolved in consensus meetings and confirmed with a third reviewer (AC).
For each study, we extracted outcome data for the placebo and drug treatment arms sepa-
rately, both at baseline and at study end. Each outcome was categorized as either an objective
(direct measurement of the patient’s abilities, e.g. a motor or memory task) or subjective
measure (a third person’s evaluation of the patient, e.g. a clinician’s rating of symptom sever-
ity). Moreover, each outcome was classified according to one of seven mental processes, or
domains: attention/executive function, language, memory, cognitive-developmental level,
autistic traits, abnormal behavior, and Global Improvement. Measured characteristics of par-
ticipants included diagnosis, physical age, IQ-level, proportion of men and women and pres-
ence of comorbid dementia. Design characteristics included design type, intervention drug(s),
country of study origin, treatment duration, number of treatment intakes daily, and year of
publication.
Data synthesis and analysis
Data management, and calculation of bias-corrected standardized mean difference (Hedges’s
g) were performed using the Comprehensive Meta-Analysis software version 3.0 (www.meta-
analysis.com).
Since considerable heterogeneity was expected, all analyses were performed with random-
effects rather than a fixed-effects model [24]. The reported Q statistic reflects the distance of
each study from the mean effect (weighted, squared, and summed overall studies). Additional
sensitivity analyses explored the effect of bias on the results. First, we assessed the presence of
publication bias visually by Funnel plot and formally by its statistical analogues, the Begg and
Mazumdar-rank correlation test. Sensitivity to the estimate of publication bias was assessed by
the Trim and Fill method.
Two types of analyses for placebo and drug effects were performed: one assessing the effect
size of pre-post treatment within each treatment arm (drug and placebo separately), the other
assessing the effect size between drug and placebo within each study. When a study provided
several outcome measures, all of them were combined to provide one value per study.
A priori defined subgroups of data were analyzed by mixed-effects analyses, using the
weighted mean effect size for each group (based on random-effect weights), to test the differ-
ence between these values (Q statistic). The subgroups were: patients with co-morbid demen-
tia/patients with no dementia, subjective/objective outcomes, type of diagnosis (FX, DS, PW)
and drug category (Ampakine, anorexic drug, GABA agonist, Growth Hormone, Inhibitor of
acetylcholine esterase, NMDA antagonist, tetracycline, thyroxine, aminoacid, vitamins).
The relationship between pre-defined continuous variable moderators (age, IQ, year of pub-
lication and trial duration) and effect size was analyzed using meta-regression, as implemented
in the Comprehensive Meta-Analysis software.
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Results
Description of studies
The total number of studies that met the inclusion criteria and were included in the final analy-
ses were k = 22 (DS k = 14; FX k = 6; PW k = 2; Williams syndrome k = 0), comprising 721
patients in the placebo arm. Fig 1 shows the trial flow and Table 1 provides descriptive features
of the studies. The mean duration of studies was 35 weeks (SD 37, range 4–156 weeks). 62% of
the participants were male, and the mean age in the placebo arm was 17.1 (SD 15.6, range
0–55) and 17.8 (SD 16, range 0–53) in the drug arm. Studies were conducted in North America
(k = 13), Europe (k = 6), Asia (k = 2), and Australia (k = 1).
Placebo and drug response
The pre-post comparison of treatment outcomes in the placebo arm of the included trials
showed a significant overall placebo response, based on study effect size (g = 0.468, SE = 0.150,
p = 0.002, see Fig 2). We identified significant heterogeneity across studies (Q = 201.9, df = 21,
p<0.001, I2 = 89.59, tau2 = 0.41), and attempted to explain this variability by means of sub-
group analyses. The same analysis was performed for the drug arm, where a pre-post compari-
son showed a significant drug response (g = 0.678, SE = 0.171, p = 0.0001). A within-study
comparison of drug and placebo (traditional drug-placebo meta-analysis) showed a non-signif-
icant difference (g = 0.061, SE = 0.052, p = 0.24). For both treatment arms, the Funnel plots
revealed no evident publication bias. The Begg’s test result was not statistically significant and
the Trim and Fill method did not lead to any adjustment of the results for the placebo arm. As
there were three studies with clearly higher effect size than the rest ([38, 40, 45]), we tested if
the placebo meta-analysis would still be significant with them removed. A random effects anal-
ysis (k = 19) revealed a significant yet smaller effect size (g = 0.2, SE = 0.071, p = 0.01) com-
pared to overall effect size when including all studies (g = 0.468).
Comparison of subjective and objective outcomes
We compared the placebo response to subjective measures (a third person’s evaluation of the
patient, e.g., clinicans or parents’ ratings of severity) with more objective outcome measures
Fig 1. Trial flow chart.
doi:10.1371/journal.pone.0133316.g001
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(direct evaluation of the patient’s abilities such as motor or memory task) in order to address
the question of report bias when responding to placebo treatment. We found significant pla-
cebo responses both for subjective (g = 0.563, SE = 0.246, p = 0.022) and objective (g = 0.434,
SE = 0.207, p = 0.036) outcomes. A comparison between objective and subjective outcomes
was non-significant (Q = 0.161, df = 1, p = 0.688), indicating that placebo responses are not sig-
nificantly greater for subjective outcomes than for objective measures.
Table 1. Study characteristics. Descriptive features of the studies included in the placebo controlled trials of the meta-analysis.
Study name Diagn. Placebo arm Drug arm Male
(%)
Study
design
Type of drug Trial duration
(weeks)
No.of
patients N
Age
Mean
Age
SD
No. of
patients N
Age
Mean
Age
SD
Bennett, 1983 [25] DS 10 10 3 10 11 2 50 Parallel Vitamins** 35
Berry-Kravis, 2006
[26]
FX 25 25 8 24 31 10 78 Parallel Ampakine 4
Berry-Kravis, 2012
[27]
FX 56 16 * 56 16 * 87 Crossover GABAB-
agonist
4
Blehaut, 2010 [28] DS 44 1 1 43 1 1 53 Parallel Vitamins** 52
Boada, 2012 [29] DS 19 23 4 18 23 4 37 Parallel NMDA-antag. 16
Ellis, 2008 [30] DS 33 0 0 106 0 0 57 Parallel Vitamins** 78
Hagerman, 1986
[31]
FX 25 16 10 25 16 10 100 Crossover Vitamins** 26
Hanney, 2012 [32] DS 74 51 7 72 52 7 57 Parallel NMDA-antag. 52
Haqq, 2003 [33] PW 12 9 3 12 9 3 50 Crossover Growth
hormone
26
Johnson, 2003
[34]
DS 9 25 8 9 30 10 58 Parallel AChEI 12
Kishnani, 2009
[35]
DS 59 26 6 56 24 5 63 Parallel AChEI 12
Kishnani, 2010
[36]
DS 65 13 2 62 13 2 52 Parallel AChEI 10
Kondoh, 2011 [37] DS 10 44 * 11 47 * 0 Parallel AChEI 24
Leigh, 2013 [38] FX 53 9 4 50 9 4 85 Crossover Tetracycline 13
Prasher, 2002 [39] DS 13 55 5 14 53 8 50 Parallel AChEI 24
Pueschel, 1980
[40]
DS 20 0 0 69 0 0 56 Parallel Vitamins** 156
Sahu, 2013 [41] FX 10 8 3 10 10 3 100 Parallel AChEI 12
Selikowitz, 1990
[42]
PW 15 14 * 15 14 * [30] Crossover Anorexic 6
Smith, 1984 [43] DS 28 11 3 28 11 3 71 Parallel Vitamins** 35
Torrioli, 2008 [44] FX 27 9.18 * 24 9.18 * 100 Parallel L-acetyl
carnitine
52
Van Trotsenburg,
2005 [45]
DS 91 0 0 90 0 0 55 Parallel Thyroxine 104
Weathers, 1983
[46]
DS 23 12 * 24 12 * 66 Parallel Vitamins** 17
Placebo controlled studies 721 17.1 15.6 828 17.8 16 62 35
* not provided
** We used “vitamins” as a category for studies using either folic acid alone or a combination of vitamins, minerals and/or antioxidants.
Abbreviations: Down Syndrome (DS), Fragile X Syndrome (FX) and Prader-Willi Syndrome (PW). Gamma-Aminobutyric acid (GABA) agonist, N-metyl-D-
aspartat (NMDA) antagonist, Acetylcholinesterase Inhibitor (AchEI).
doi:10.1371/journal.pone.0133316.t001
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Effect of mental processes categories
The effect size of the placebo response differed significantly by different mental process catego-
ries (Q = 13.288, df = 6, p = 0.039). Table 2 shows the results observed for each category. The
pre-post comparison for autistic traits, abnormal behavior, cognitive and developmental skills
and Clinical Global Improvement showed a significant placebo response. However, no signifi-
cant placebo response was observed on attention, language and memory. The drug response
also differed significantly by mental process categories (Q = 17.348, df = 6, p = 0.008). No
significant category difference was seen between drug and placebo.
Fig 2. Forest plot of placebo responses in patients with Intellectual Disability. A significant placebo
response was found from pre to post treatment (p = 0.002) across all studies. If studies included more than
one outcomemeasure they were combined into one value. A random-effects model was used to calculate
significance. There was a medium overall effect size, which is comparable to the placebo effect size in
studies with patients who are not intellectually disabled [47, 48].
doi:10.1371/journal.pone.0133316.g002
Table 2. Placebo and drug responses bymental process categories. The total number of scales used for assessment of treatment outcomes were
grouped into 7 different mental process categories, or domains. Four out of seven domains had a significant placebo response and five out of seven domains
had a significant drug response. Clinical Global Impression (CGI) assessments are commonly used as study endpoints in clinical trials. Here, CGI is repre-
sented by one category, even if it is not a mental process.
Placebo response Drug response Drug / Placebo comparison
Mental process g SE p-value g SE p-value Q df(Q) p-value
Attention (k = 2) 0.056 0.229 0.81 0.180 0.234 0.441 0.143 1 0.71
Language (k = 8) 0.017 0.064 0.79 0.121 0.063 0.05* 1.327 1 0.25
Memory (k = 4) 0.174 0.132 0.19 0.282 0.159 0.08 0.272 1 0.60
Cognitive and developmental (k = 17) 0.305 0.121 0.01* 0.521 0.137 0.0001**** 1.394 1 0.24
Abnormal Behavior (k = 7) 0.278 0.09 0.002*** 0.480 0.127 0.0001**** 1.686 1 0.19
Autistic traits (k = 3) 0.336 0.161 0.037* 0.394 0.142 0.006** 0.073 1 0.79
CGI (k = 3) 2.215 1.049 0.035* 2.004 0.800 0.01* 0.026 1 0.87
* < .05
** < .01
*** < .005
**** < .001
doi:10.1371/journal.pone.0133316.t002
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Effect of Intelligence level (IQ) on treatment outcomes
Using a regression model, we assessed the effect of IQ (which varied from 20 up to 65) on treat-
ment response and found a significant effect of IQ corrected for age on placebo responses
(Q = 7.48, df = 2, p = 0.02), represented by larger placebo responses in patients with higher IQ.
There was no similar effect for drug response (Q = 0.46, df = 2, p = 0.80).
Effect of age on treatment outcomes
There was a significant effect of age on placebo effect size (Q = 5.25, df = 1, p = 0.02), indicating
that younger patients had larger placebo responses (Fig 3). We found a comparable effect of
age on drug effect size (Q = 8.56, df = 1, p = 0.0034).
Effect of dementia on treatment outcomes
Comorbid dementia in patients with ID had a significant effect on placebo responses
(Q = 4.249, df = 1, p = 0.039), but not on drug responses (Q = 1.961, df = 1, p = 0.161). Specifi-
cally, patients with no dementia showed robust placebo responses (g = 0.508, SE = 0.160,
p = 0.002) whereas patients with comorbid dementia had virtually no response to placebo (g =
-0.050, SE = 0.218, p = 0.82).
Regression with trial duration
We found a positive effect of trial duration on placebo effect size (Q = 16.38, df = 1,
p = 0.0001), with results pointing to larger effect sizes with longer trial durations. Two outliers
appeared to drive the effect [40, 45] and with them removed the effect of trial duration was
non-significant. Nonetheless, removal of these outliers did not affect the observation that the
placebo response did not diminish over time. This finding is contrary to the common belief
that placebo responses would be short lasting and wane with time [49].
Fig 3. Effect of age on placebo effect size. There was a significant effect of age on placebo effect size (g),
represented by higher placebo responses in the youngest patients included in this meta-analysis (p < .05). It
is possible that the results are explained by stronger placebo-by-proxy effects in young children, as parents
and caregivers express high encouragement, attention and support to babies. The intensive care and
attention given to young children may wane over time and thus lessen the placebo effects in older ID patients.
doi:10.1371/journal.pone.0133316.g003
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Effect of diagnosis category
The effect size of the placebo response differed significantly between diagnostic categories
(Q = 7.367, df = 2, p = 0.025). Placebo responses were observed both in DS (g = 0.510,
SE = 0.198, p = 0.01) and FX (g = 0.590, SE = 0.273, p = 0.03), but not in PW patients (g =
-0.154, SE = 0.199, p = 0.44). The number of studies included in the PW group was likely too
small (k = 2) to allow enough statistical power to this analysis. Conversely, the effect size of the
drug response did not significantly differ by diagnosis category (Q = 3.722, df = 2, p = 0.16).
Regression with year of publication
The possible effects of time on the development of drugs with high efficacy, and the associated
increase in treatment expectations conveyed to patients and their families, was assessed by a
regression of treatment effect size and publication year, ranging from 1980 to 2013. We did not
find any effect of the year of publication and effect size, neither in placebo (Q = 0.06, df = 1,
p = 0.81), nor drug (Q = 1.34, df = 1, p = 0.25).
Effect of drug category
A regression model revealed that the effect size of both placebo and drug responses differed sig-
nificantly by drug category (placebo Q = 158.243, df = 9, p = 0.0001 and drug Q = 144.433,
df = 9, p = 0.0001 respectively). Unpacking the overall regression model shows that trials
involving either a GABA agonist, Inhibitor of acetylcholine esterase, tetracycline, thyroxine, L-
acetyl carnitine or vitamins had a significant drug response. Among them, the trials involving
an inhibitor of acetylcholine esterase did not show a comparable placebo response, possibly
related to the presence of patients with comorbid dementia in these studies.
Discussion
To our knowledge, this meta-analysis presents the first account of placebo responses in ID
patients and the first evaluation of the role of IQ in placebo mechanisms. Here, we demonstrate
that patients with ID display significant placebo responses in spite of severe impairment of
mental abilities such as learning, reasoning, abstract thinking and predicting the future. The
overall effect size of placebo responses in this study (g 0.5) is considered a “medium” effect and
is comparable to the placebo response in adult patients without ID [47, 48] and in children
[50] across a range of domains such as migraine, depression, Attention Deficit Hyperactivity
Disorder and osteaoarthritis. Previous meta-analyses have used the same approach to studying
placebo responses in different clinical populations, using data from the placebo arm of RCTs in
e.g. depression [51], irritable bowel syndrome [52], restless legs [53], and schizophrenia [54].
The strong evidence for placebo responses in ID, illustrated both in subjective and more objec-
tive outcomes, and in a wide range of behavioral and cognitive domains, challenges current
theories of placebo mechanisms and suggests possibilities for change in the delivery of care.
The fact that there was no significant difference in placebo effect size between subjective and
objective outcome measures suggests that placebo responses in ID is not an effect of report
bias, but likely represents a true improvement of patients’ symptoms. Conversely, if placebo
effects had mainly been present in response to subjective reports (given by caretakers with no
intellectual deficiency) one could not have concluded that individuals with ID display placebo
responses. Given the refractory nature of genetically determined ID, it seems reasonable to
assume that the improvements in response to placebos are primarily related to the provision
and context of care, and not to natural remission of ID symptoms. This suggests that a support-
ive and attentive environment may lead to improvements in patients with ID.
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The traditional drug versus placebo meta-analysis did not reveal any significant difference
between drug and placebo. It is interesting to note that, we found a significant drug response
from baseline in the drug arm. It is likely that this drug effect, which reflects both drug effect
per se and placebo responses, is primarily related to placebo responses we observed in these
studies.
Possible mechanisms of placebo responses in ID
This meta-analysis only included genetically determined ID, i.e. a condition that existed from
conception, thus ensuring that the observed placebo response was not confounded by patients
with a normal brain development before onset of ID. One key mechanism of placebo responses,
described in individuals without ID, involves conscious expectancy [55]. The content of infor-
mation related to treatment, such as referring to a topical placebo cream as “inert and with no
effect” or as a “powerful painkiller” [56], can manipulate expectation and mediate placebo
effects. Yet, it seems unlikely that the explicit information content play a major role in generat-
ing placebo responses in patients with ID, given their specific reasoning and language difficul-
ties (both in comprehension and production).
Placebo effects can also be induced by mechanisms that are automatic and operate on a
non-conscious level, such as associative learning (conditioning) [57]. Placebo responses have
also been demonstrated in treatment of animals [58, 59]. In a previous study we challenged the
exclusive role of conscious cognitions in human placebo responses and suggest that treatment
cues may be implicitly embedded in the patient–clinician interaction and clinical environment
[22, 23]. It is likely that non-conscious placebo mechanisms may play a role in patients with
ID, as they involve learning that does not rely on abstraction.
Closely related to non-conscious placebo effects, and a third possible mechanism, is the
implicit social influence of “placebo by proxy” [60], which has been mentioned apropos of pla-
cebo effects in young children. Placebo by proxy can operate in two ways. It might produce a
genuine change in the patient’s condition, and/or it might alter the parent or caregiver’s
perception of the patient’s behavior [61]. The significant placebo response we observed on sub-
jective outcomes (evaluation of the patient by a third person) are likely related to the latter.
Grelotti and Kaptchuk argue that “if clinicians and family members feel empowered and opti-
mistic about a treatment, they may smile more, pay more attention to the patient, promote treat-
ment adherence, encourage the patient to engage in new activities etc” [60]. In this way, Grelotti
and Kaptchuk suggest that placebo by proxy changes the patient’s psychosocial context, and
mediates the placebo effect in a way that is not strictly a learning phenomenon or conscious
expectancy; yet it may have the same profound influence on patient’s physiology. Placebo by
proxy has also been observed in children with tantrums [61], autism [62], cerebral palsy and
Attention-Deficit/Hyperactivity Disorder (ADHD) [63] and it is likely that this mechanism
play a major role in ID trials, as ID patients are very sensitive to changes in their environment
[64–66]. In the case of placebo by proxy, it is the treatment expectations of the clinicians and
family members that elicit a placebo effect on the ID patient mediated by altered behavior
toward him.
Contrary to our findings, a previous study speculated that ID patients would not display pla-
cebo responses, as there is evidence for loss of placebo responses in patients with dementia
(due to impaired cognitive functioning) [67]. This furthers the notion that patients with geneti-
cally determined ID may have developed an alternate mechanism for placebo responses that
relies on an early compensatory adaption. As ID patients are born with cognitive impairments,
it is likely that adaptive responses to the challenges in the environment occur with time. In
dementia however, already established response patterns are disrupted, leaving the patient with
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severe cognitive disabilities. Along these lines, the placebo responses in ID patients could be
described as a “low road” adaptation, which is not related to higher-order cognitive function
(possibly through patients’ enhanced sensitivity to contextual and social cues), compared to
the “high road” predictions and expectations described in healthy individuals.
IQ
Even if patients with ID display robust overall placebo responses, there was a significant effect
of IQ on placebo effect size (but not on drug effect size). It is possible that high-functioning ID
patients have a normal placebo response, but at a certain degree of intellectual impairment
there is no longer a response. Since a limited number of clinical trials reported IQ levels for
their patients, our findings should be confirmed in future analysis where the relationship
between IQ and placebo responses can be further explored. We found that ID patients dis-
played significant placebo responses before, but not after, onset of dementia, confirming the
previous mentioned study suggesting decreased placebo responses related to severe loss of cog-
nitive skills in patients with dementia [67].
Trial duration
Placebo effects are anecdotally thought to have a short duration, as they rely on learning mech-
anisms that may wane with time [49]. Here, we found that the placebo responses were stable
over time, in spite of trials lasting up to three years. This is in line with the stable placebo effects
seen in various long lasting clinical trials [68, 69]. We hope that future studies will investigate
the long-term effects of placebo treatment in ID patients.
Syndrome-related specificities
We found placebo responses both in DS and FX patients, but cannot conclude anything about
PW given the small number of studies. DS and FX patients both exhibit a moderate to severe
range of ID but have different social and affective profiles. DS patients are frequently reported
to demonstrate empathy and care for others, showing concern and offering comfort to the per-
son in distress [70], while FX patients display social hyper-arousal, which leads to gaze aver-
sion, social difficulties and anxiety [71, 72]. In both syndromes, ID patients usually would like
to please their doctor and caretaker [73]. Both DS and FX patients are sensitive to surrounding
cues of expectancy, even if it may be from different disorder-specific abilities (e.g. good social
and communicative skills in DS; and lack of inhibition or filtering of the environment in FX)
[74–77].
Age
We found a significant relationship between age and placebo effect size, with higher placebo
responses in very young children. Four trials included children at birth and it is likely that the
high placebo response is an effect of a particularly intensive placebo by proxy in newborns. A
recent review suggests an inverse relationship between age and placebo effect size in healthy
children [50], validating our findings in patients with ID. Children tend to assume that they are
receiving real medication more often than adults [78] and meta-analyses across several medical
disciplines report robust placebo responses in children [50, 79–81].
Placebo in different cognitive and behavioral domains
The placebo effect differed significantly by mental process categories. Even if this could partly
be an effect of the different scale sensitivities, it is possible that placebo responses are not
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equally expressed across domains. Many different scales were used in the different clinical trials
included here. Future work is necessary (as suggested by the recent meeting convened by the
National Institutes of Health, Washington DC, 2012) in order to identify reliable and sensitive
outcome measures for common use in clinical trials in FX [82] and more generally in ID patients.
Limitations and future perspectives
As previously mentioned, there is always a possibility that the placebo response is partially rep-
resented by spontaneous remission, or the natural history of the condition being treated. How-
ever, this study only includes patients with genetically determined ID, which is a condition
without spontaneous remission [2]. Nevertheless, even if the intellectual disability will not
improve over time, some comorbid symptoms may fluctuate over time, such as tantrums,
hyperactivity or agitation [73]. As some of them may be included as outcome measures to eval-
uate the behavior of the patients, it is likely that these outcomes may be more sensitive to pla-
cebo too. If future pharmacological trials include a natural history control arm, in addition to
the traditional placebo control arm, there can be a better estimation of the possible contribu-
tions of bias to the placebo response.
No significant drug versus placebo effect was observed in our meta-analysis. Yet, novel and
hopefully more efficient treatment options for ID are beginning to appear for a number of spe-
cific conditions, such as DS and FX [3]. These pathophysiologically targeted treatments are
focusing on correcting the underlying defect, via re-equilibration of the biochemical imbalance
that results from genetic mutations, instead of suppressing only some of the most pervasive
symptoms [83]. Some preliminary results have been promising [84] and raised the expectancy
in patient’s families. Given the recent example of secretine trials in children with autism [62,
63], showing robust and consistent reductions in symptoms, but no difference between secre-
tine over placebo, it is necessary to be vigilant on the role of placebos when testing novel treat-
ments in ID.
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